Dynavax Technologies Corp. (NASDAQ: DVAX), a biotechnology company, has signed a contract to endow the company with the right to commercialize the hepatitis B vaccine in Germany and the EU in the future.
Last week, Dynavax Technologies announced that it had entered into a collaboration agreement to market and distribute its hepatitis B vaccine (Heplisav B) with the German company Bavarian Nordic. In February 2021, Dynavax received approval from the EU regulatory body to sell Heplisav B. The operation in Germany marks the first step in disseminating the advanced development in the region.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Heplisav B contains only two doses (instead of the usual three) and has greater effectiveness than competing products – about 95 percent. The demand for affordable hepatitis B vaccines is high worldwide, so Heplisav B is selling well. Hepatitis B vaccination is still relevant today. More than 250 million people have been infected by the virus worldwide, and the transmission rate is rapidly increasing. Dynavax Technologies does not have to increase its sales in Germany, as Bavarian Nordic already has a strong marketing and distribution network in that market. Heplisav B is expected to enter the German market in the fourth quarter of this year.
Dynavax Technologies Corp. (NASDAQ: DVAX) produces and seeks to commercialize products based on immunostimulatory sequences. With approaches that specifically alter the immune system’s response, the company has developed products for treating and preventing allergies, infectious and chronic inflammatory diseases. Similarly, Dynavax Technologies is developing a vaccine against COVID-19, and the results of its clinical trial will be announced by the end of 2021.
At last check-in after-market trading, Dynavax Technologies Corporation (DVAX) shares were down -0.24% at $8.0908. DVAX’s stock closed the last session at $8.11, decreasing -1.10% or -$0.09. The stock traded between $8.08 and $8.41 during the day. A total of 1.79 million shares exchanged hands, which was lower than the firm’s 50-day daily volume of 2.78 million and lower than its annual volume of 4.73 million. Its stock has advanced 2.40% over the past 12 months, and it gained 5.05% in the last week. Within the last six months, the stock gained 69.31%, and within the last three months, it has lost -6.13 percent. Since the beginning of the year, the stock has returned 82.25%.
